Pipeline
NETRIS Pharma is conducting an extensive Clinical Development Plan with its lead asset NP137 and developing a pipeline of drugs targeting different ligands of Dependence Receptors.
Pipeline
| Program Target | Indication | Discovery | IND Enabling | Phase I | Phase II | Late-Stage Development |
|---|---|---|---|---|---|---|
|
NP137
Netrin-1
|
All advanced tumors |
|||||
|
NP137 + Pembro(*)/Carbotaxol
Netrin-1
|
Endometrium / Cervix |
|||||
|
NP137 + Approved Immune Checkpoint
Netrin-1
|
Basket: • NSLCC |
|||||
|
NP137 + Atezo-Bev
Netrin-1
|
Liver |
|||||
|
NP137 + Folferinox
Netrin-1
|
Pancreas |
|||||
|
NP137P
Netrin-1
|
Non cancer indication |
|||||
|
NP137R
Netrin-1
|
Netrin-1 expressing cancer |
|||||
|
NP701
Undisclosed target
|
Hedgehog expressing cancer |
|||||
|
NP100
Undisclosed target
|
Glioblastoma |
Clinical Development
NETRIS Pharma’s clinical development plan includes five ongoing clinical trials, which have the ambition to demonstrate the ability of the lead asset NP137 to alleviate the resistance to current standard of cares such as chemotherapies, targeted therapies or immune checkpoints inhibitors. NETRIS Pharma benefits from a long-term collaboration with the Leon Bérard Comprehensive Cancer Center, which has a unique set of multidisciplinary technological platforms. This collaboration offers NETRIS Pharma the ability to conduct ambitious ancillary research, ranging from immune infiltrate identification to single cell RNA sequencing with the goal to identify Biomarkers. Development of relevant Biomarker’s is a critical part of NETRIS Pharma’s efforts to fight cancer. Our focus is to identify relevant biomarkers of our target’s engagement in the disease progression, and biomarkers which are predictive of a patient response to therapy.
